Dementia medications should be reassessed regularly—typically every 3 to 6 months, or whenever there’s a noticeable change in the person’s cognitive status, behavior, or overall health. Unlike medications for other chronic conditions that reach a stable dose and remain effective long-term, dementia medications require ongoing evaluation because the disease itself is progressive and the person’s needs change over time. A medication that worked well six months ago may need adjustment, discontinuation, or replacement as the condition advances or as new symptoms emerge.
The timing and triggers for reassessment are driven by several factors: how rapidly the person’s dementia is progressing, what medications they’re taking, whether they’re experiencing side effects, and how they’re responding to treatment. For example, if someone taking donepezil for Alzheimer’s disease develops tremors or gastrointestinal problems, their doctor might switch them to a different cholinesterase inhibitor or lower the dose. Reassessment isn’t about finding the perfect dose once and stopping; it’s an ongoing process that reflects the reality of living with a degenerative neurological condition.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Key Triggers That Warrant Immediate Medication Reassessment
- Monitoring Medication Effectiveness Over Time
- Side Effects and Tolerability as Reassessment Drivers
- Coordinating Reassessment with Your Doctor and Care Team
- The Risk of Inappropriate Medication Use in Dementia
- Changes in Life Circumstances and Reassessment
- Long-Term Effectiveness and the Plateau Effect
- Frequently Asked Questions
Key Triggers That Warrant Immediate Medication Reassessment
Certain changes in a person’s condition or circumstances signal that it’s time to reassess dementia medications without waiting for the routine review. If someone experiences a sudden worsening of memory, confusion, or behavioral changes—such as new agitation, withdrawal, or hallucinations—the medication regimen should be evaluated to determine whether the medication is losing effectiveness or whether something else (like an infection, nutritional deficiency, or sleep disorder) is contributing. Similarly, the appearance of new or worsening side effects is a clear trigger for reassessment. A person who develops dizziness, falls, excessive drowsiness, or loss of appetite on their current medications may need dose adjustments or a switch to a different drug.
Hospital admissions also demand reassessment. During a hospitalization for infection, surgery, or another acute illness, medications often get changed, additional drugs are introduced, and the person’s baseline condition may shift. Many family members find that their relative’s dementia seems to have suddenly worsened after a hospital stay, when in reality the medication regimen has been altered without clear coordination with the primary dementia care provider. It’s essential to review all medications carefully after discharge and reconcile them with what the person was taking before. Another major trigger is a significant life change—a move to assisted living or a memory care facility, a loss of a primary caregiver, or the onset of a new medical condition like heart disease or diabetes—because these events can alter how medications are metabolized or managed.
Monitoring Medication Effectiveness Over Time
Dementia medications don’t stop the disease; they may slow cognitive decline or help manage symptoms for a period, but their benefit is not permanent. Cholinesterase inhibitors like donepezil, rivastigmine, and galantamine are typically used in mild to moderate Alzheimer’s disease, while memantine may be added or used alone in moderate to severe cases. A person might show clear improvement or stabilization in the first few months of taking one of these medications—better concentration, fewer episodes of confusion, or improved ability to engage in conversations. However, as the underlying disease progresses, the medication’s effectiveness may plateau or diminish. After 12 to 18 months, some people show no additional benefit from their current medication, and the doctor may consider increasing the dose, adding a second medication, or switching to something else.
A critical limitation is that there’s no simple blood test or biomarker that tells us when a medication has stopped working. Reassessment relies on careful observation of the person’s day-to-day functioning—how they perform on cognitive tests, whether they’re managing activities of daily living, and how they’re behaving. family members often provide crucial information that the person themselves cannot, since memory loss and impaired insight are core features of dementia. If a caregiver notes that their loved one has stopped recognizing family members or has become unable to follow simple instructions, that’s relevant to whether the current medication regimen is still appropriate. Some families find it helpful to keep a brief log of cognitive and behavioral changes between doctor visits to provide concrete information during reassessment discussions.
Side Effects and Tolerability as Reassessment Drivers
Even if a medication is technically working to slow cognitive decline, it may become intolerable due to side effects, and that’s a legitimate reason for reassessment and change. Cholinesterase inhibitors frequently cause nausea, vomiting, diarrhea, or loss of appetite, especially when first started or when doses are increased. Some people experience vivid dreams, depression, or emotional lability. Memantine can cause dizziness, headaches, confusion, or constipation.
For a person with advanced dementia, many of these side effects are particularly problematic—a person who can’t communicate well may become more agitated or withdrawn if they’re experiencing nausea, and gastrointestinal problems can lead to weight loss and nutritional decline, which then accelerates cognitive and functional deterioration. The challenge is distinguishing between side effects from the medication and changes caused by disease progression or other medical conditions. If a person becomes more irritable, that could be a sign of depression (a medication side effect), but it could also reflect advancing dementia or an untreated medical problem like pain or constipation. During reassessment, the doctor will take a medication history, review timing of symptom onset, and often consider dose adjustments or medication changes to see if the situation improves. For example, a person taking standard-dose donepezil who develops severe nausea might be switched to the transdermal patch formulation, which some people tolerate better, or the dose might be reduced if the goal is simply to manage behavioral symptoms rather than slow cognitive decline.
Coordinating Reassessment with Your Doctor and Care Team
Effective medication reassessment requires clear communication between the person with dementia (when possible), family caregivers, and all healthcare providers involved in care. Many people with dementia see multiple doctors—a primary care physician, a neurologist or geriatrician, possibly a psychiatrist—and not all of them may be aware of every medication change or concern.
Before a reassessment appointment, it’s helpful to prepare a list of specific observations: when changes in cognition or behavior began, what side effects have appeared, how the person is functioning with activities like eating, dressing, and hygiene, and any falls or near-falls. This concrete information is far more useful to the doctor than vague statements like “they seem worse.” During reassessment, ask the doctor to explain their thinking clearly: Is the current medication still helping, or is it time to try something else? If the dose is being changed, what should the family watch for, and how long will it take to see a difference? If a medication is being stopped, will there be a gradual tapering or an immediate discontinuation? (Some medications, particularly those that affect neurotransmitters, should be tapered rather than stopped abruptly to avoid rebound effects.) Understanding the rationale behind medication decisions helps caregivers support adherence and monitor for effects more effectively. It also helps when reassessment leads to difficult conversations—like when a doctor recommends discontinuing medication because the person’s dementia has advanced to a stage where the medication is unlikely to help and side effects may cause more harm than benefit.
The Risk of Inappropriate Medication Use in Dementia
One common problem encountered during reassessment is polypharmacy—the use of many medications simultaneously—which is particularly risky in people with dementia. Older adults with dementia are highly sensitive to medications and their interactions; they may metabolize drugs differently, have reduced kidney or liver function, and be unable to report side effects clearly. A person taking a cholinesterase inhibitor for dementia plus a medication for high blood pressure plus a sleep aid plus pain medication plus a gastrointestinal medication may be experiencing side effects from the interactions between these drugs rather than from any single medication, yet family and doctors may not realize it.
During reassessment, it’s important to conduct a “medication audit”—a systematic review of every medication to ask: Is it still needed? Is the dose appropriate for this person? Could it be causing or contributing to the side effects we’re seeing? Another risk is the inappropriate use of antipsychotics or sedating medications to manage behavior in dementia. These drugs are sometimes prescribed to calm agitation, aggression, or wandering, but they carry serious risks in people with dementia, including increased stroke risk, cognitive decline, and falls. Many guidelines recommend trying non-medication approaches first—like identifying triggers for behavior, increasing physical activity, modifying the environment, or addressing pain or other underlying causes—before resorting to psychiatric medications. During reassessment, if an antipsychotic or sedative has been prescribed, the doctor should carefully evaluate whether it’s still necessary and whether it can be safely reduced or discontinued, particularly if the behavior that prompted its use has improved or if the person’s health has otherwise changed.
Changes in Life Circumstances and Reassessment
A move to a memory care facility, the death of a spouse, or the onset of a new medical condition all warrant reassessment of dementia medications. When someone transitions from home care to facility-based care, their medication adherence, nutrition, sleep patterns, and social engagement often change significantly—sometimes improving, sometimes worsening. These changes can affect how medications work. If someone moves to a facility where they’re more socially engaged and physically active, their behavioral symptoms might improve, potentially reducing the need for behavioral medications. Conversely, the loss of familiar surroundings and caregivers can increase agitation and confusion, requiring reassessment of current medications and possibly adjustments.
The development of a serious medical illness—such as heart failure, kidney disease, or diabetes—also necessitates reassessment. Some dementia medications can worsen these conditions or interact with medications used to treat them. A person newly diagnosed with heart failure, for instance, may need to be carefully monitored while taking cholinesterase inhibitors, which can have cardiac effects. The dosing of memantine may need adjustment if kidney function declines. These medical changes require coordination between the dementia care provider and other specialists to ensure the medication regimen is safe and appropriate given the full picture of the person’s health.
Long-Term Effectiveness and the Plateau Effect
Many families expect that dementia medications will continuously improve their loved one’s condition, but the reality is that these medications typically show benefits early on and then the effect plateaus—a person may stabilize for a period but won’t return to prior levels of function. After six months to a year of treatment with a cholinesterase inhibitor, some people show no further improvement on cognitive testing, and the caregiver may wonder if the medication is still working. At this point, reassessment involves determining whether to continue the current medication, increase the dose, add another medication, or make a change.
The decision depends on whether the medication is preventing further decline (which is hard to know for certain, since we can’t see what would have happened without it) or whether it’s simply maintaining the current status. For medications prescribed late in the disease course—such as starting memantine in advanced dementia when someone is already nonverbal and bedbound—reassessment is particularly important because the evidence for benefit is weaker and the risk of side effects may outweigh any potential advantage. A doctor might recommend continuing a medication because stopping it could cause withdrawal symptoms or a rebound worsening, even if the medication itself is no longer providing meaningful cognitive or functional benefit. This is another area where open, honest communication between the care team and family is essential; the goal shifts from slowing decline to comfort and quality of life, and medication decisions should reflect that shift.
Frequently Asked Questions
How often should my loved one’s dementia medication be reviewed?
The standard recommendation is every 3 to 6 months, or sooner if there’s a noticeable change in cognition, behavior, or side effects. Some doctors review more frequently in the first months after starting a medication, then less often if the person is stable. However, any significant life change—a hospitalization, a move, a new medical diagnosis—should trigger an earlier review.
What happens if a dementia medication stops working?
If a medication is no longer providing benefit or has become ineffective as the disease progresses, the doctor might increase the dose, add a second medication, switch to a different medication, or discontinue it entirely. The decision depends on the person’s current stage of dementia, other medical conditions, and what symptoms need managing most.
Can dementia medications be stopped?
Yes, medications can be stopped, either gradually or immediately depending on the drug and the reason. If a person is experiencing significant side effects or if the medication is no longer beneficial and quality of life is the priority, discontinuation may be appropriate. Some medications should be tapered rather than stopped abruptly.
Who should be involved in medication reassessment?
Ideally, the person’s primary care doctor or neurologist, any specialists involved in care, the person with dementia (if they’re able to participate), family caregivers, and the person providing day-to-day care. Pharmacists can also provide valuable input on potential interactions and side effects.
Are there risks to staying on the same dementia medication for years?
Possible risks include reduced effectiveness over time as the disease progresses, cumulative side effects, medication interactions if other drugs are added, and the person potentially having outgrown the indication for that particular medication. Regular reassessment helps catch these issues early.
What should I tell my doctor before a medication reassessment appointment?
Provide specific, concrete observations: changes in memory, confusion, or behavior; any new symptoms or falls; side effects; how the person is managing daily activities; and any recent hospitalizations or new medical diagnoses. Written notes are more helpful than general impressions.
